AMT Receives EMEA Orphan Drug Designation For Acute Intermittent Porphyria
Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, announced that the European Medicines Agency has granted Orphan Drug Designation to AMT’s gene therapy product AMT-021 for the treatment of acute intermittent porphyria (AIP).
More: continued here
Filed under: Endocrinology on June 1st, 2009
You must be logged in to post a comment.